Moleculin Stock Crashes 64% on Deeply Discounted $9.3M Offering
MBRX sits 33% above its 52-week low of $0.312 on elevated volume (22× avg).
Summary
Moleculin priced a $9.3 million public offering at $0.75 per share — a massive discount to the prior close — sending the stock down 64%. The offering includes warrants for up to 37 million additional shares, adding significant dilution risk for a company with a market cap around $5.4 million. This follows the S-1/A filed yesterday seeking roughly $9.1 million at $2.19 per share; the final pricing came in far lower, reflecting weak demand. Concurrently, the company released updated blinded MIRACLE trial data showing a 37% composite complete remission rate in 62 evaluable R/R AML patients, with consistent responses in the 48% who failed prior AbbVie's Venclexta. While the efficacy signal remains encouraging, the financing terms underscore the company's desperate cash position — it needs $25 million to continue as a going concern. Full data unblinding is expected between December 2026 and February 2027.
At the time of this announcement, MBRX was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.31 to $18.25. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Benzinga.